Lilly’s latest China drug deal; Immunovant’s setback in lupus

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 24 Sept, 14:14 UTC

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

science

Sources

• T2Lilly’s latest China drug deal; Immunovant’s setback in lupusBioPharma Dive / Healthcare Dive / MedTech Dive24 Sept, 14:14